7 completed, 1 terminated. 8 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 7, Terminated 1 |
| Phase 2 | 6 | Completed 6 |
Follow Contrave: new trials by email Literature Review of Contrave trials Research Report on Contrave
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Naltrexone and Bupropion (NB) medication, Placebo - Loss-of-Control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 24 | 2022-06-10 | 2026-08-26 |
| Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo - Loss-of-control Eating, Obesity/Overweight | Phase 2 / Phase 3 | Completed | Yale University | 92 | 2021-06-29 | 2026-08-26 |
| Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo - Binge-Eating Disorder | Phase 2 / Phase 3 | Completed | Yale University | 89 | 2018-04-17 | 2024-04-03 |
| Individualized Obesity Pharmacotherapy Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion - Obesity | Phase 3 | Completed | Mayo Clinic | 193 | 2017-12-11 | 2023-07-18 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment) - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 31 | 2017-09-05 | 2024-02-01 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy NB medication (Naltrexone Bupropion combination), Placebo - Binge-Eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 68 | 2017-08-28 | 2024-02-02 |
| Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo - Binge-eating Disorder, Obesity | Phase 2 / Phase 3 | Completed | Yale University | 136 | 2017-02-27 | 2023-03-08 |
| Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) NB32, PBO, Weight Management Program - Obesity, Overweight | Phase 3 | Terminated | Orexigen Therapeutics, Inc | 8910 | 2012-06-01 | 2017-02-27 |
Obesity (7) · Binge-Eating Disorder (4) · Overweight (3) · Body Weight (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Heart Diseases (1) · Metabolic Diseases (1) · Nutrition Disorders (1) · Overnutrition (1)
Yale University (6) · Mayo Clinic (1) · Orexigen Therapeutics, Inc (1)
United States (8)
Carlos M Grilo, PhD (3) · Andres J Acosta (1) · Carlos Grilo, PhD (1) · Sherry McKee, PhD (1) · Valentina Ivezaj, Ph.D. (1)
PMID 26954408, PMID 33759389, PMID 36285406
R01DK049587 (3), R01DK126637 (2), R01DK112771 (1)